Back to Search
DR. DAVID J BEARSS M.D.
M.D.
Pediatrics Physician
NPI: 1063408235IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
9600858(NC)
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
9600858(NC)
Education
OTHER
Class of 1992
Research & Publications (20)
Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
PMID 11929828·Cancer Res·2002
7-preclinical
Telomere maintenance mechanisms as a target for drug development.
PMID 11426649·Oncogene·2000
6-review
Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
PMID 10713698·Oncogene·2000
7-preclinical
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
PMID 19432987·BMC Cancer·2009
7-preclinical
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.
PMID 18815537·Pancreas·2008
7-preclinical
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
PMID 17325667·Oncogene·2007
8-other
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
PMID 16891462·Mol Cancer Ther·2006
8-other
Aurora-A over-expression in high-grade PIN lesions and prostate cancer.
PMID 15754349·Prostate·2005
8-other
Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue.
PMID 15696627·Proc Natl Acad Sci U S A·2005
8-other
alpha-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells.
PMID 14991239·Cancer Immunol Immunother·2004
7-preclinical
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.
PMID 15078988·Mol Cancer Ther·2004
8-other
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
PMID 15141022·Mol Cancer Ther·2004
8-other
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.
PMID 15281905·Curr Med Chem Anticancer Agents·2004
7-preclinical
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
PMID 15374984·Cancer Res·2004
7-preclinical
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
PMID 15454230·Bioorg Med Chem Lett·2004
8-other
p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
PMID 12589033·Mol Cancer Ther·2003
7-preclinical
Telomere inhibition and telomere disruption as processes for drug targeting.
PMID 12540745·Annu Rev Pharmacol Toxicol·2003
6-review
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
PMID 12657723·Mol Cancer Ther·2003
4-observational
Structure-based design of novel anti-cancer agents targeting aurora kinases.
PMID 12678912·Curr Med Chem Anticancer Agents·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via NOVANT HEALTH MEDICAL GROUP, LLC · 2 locations total
- Address
- 825 W HENDERSON ST
SALISBURY, NC 28144 - Phone
- (704) 637-1123
Quick Facts
- NPI
- 1063408235
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile